This page has only limited features, please log in for full access.

Unclaimed
Lisa Oestereich
German Center for Infectious Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, 20359 Hamburg, Germany

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Journal article
Published: 24 May 2021 in Viruses
Reads 0
Downloads 0

Several of the human-pathogenic arenaviruses cause hemorrhagic fever and have to be handled under biosafety level 4 conditions, including Lassa virus. Rapid and safe inactivation of specimens containing these viruses is fundamental to enable downstream processing for diagnostics or research under lower biosafety conditions. We established a protocol to test the efficacy of inactivation methods using the low-pathogenic Morogoro arenavirus as surrogate for the related highly pathogenic viruses. As the validation of chemical inactivation methods in cell culture systems is difficult due to cell toxicity of commonly used chemicals, we employed filter devices to remove the chemical and concentrate the virus after inactivation and before inoculation into cell culture. Viral replication in the cells was monitored over 4 weeks by using indirect immunofluorescence and immunofocus assay. The performance of the protocol was verified using published inactivation methods including chemicals and heat. Ten additional methods to inactivate virus in infected cells or cell culture supernatant were validated and shown to reduce virus titers to undetectable levels. In summary, we provide a robust protocol for the validation of chemical and physical inactivation of arenaviruses in cell culture, which can be readily adapted to different inactivation methods and specimen matrices.

ACS Style

Silke Olschewski; Anke Thielebein; Chris Hoffmann; Olivia Blake; Jonas Müller; Sabrina Bockholt; Elisa Pallasch; Julia Hinzmann; Stephanie Wurr; Neele Neddersen; Toni Rieger; Stephan Günther; Lisa Oestereich. Validation of Inactivation Methods for Arenaviruses. Viruses 2021, 13, 968 .

AMA Style

Silke Olschewski, Anke Thielebein, Chris Hoffmann, Olivia Blake, Jonas Müller, Sabrina Bockholt, Elisa Pallasch, Julia Hinzmann, Stephanie Wurr, Neele Neddersen, Toni Rieger, Stephan Günther, Lisa Oestereich. Validation of Inactivation Methods for Arenaviruses. Viruses. 2021; 13 (6):968.

Chicago/Turabian Style

Silke Olschewski; Anke Thielebein; Chris Hoffmann; Olivia Blake; Jonas Müller; Sabrina Bockholt; Elisa Pallasch; Julia Hinzmann; Stephanie Wurr; Neele Neddersen; Toni Rieger; Stephan Günther; Lisa Oestereich. 2021. "Validation of Inactivation Methods for Arenaviruses." Viruses 13, no. 6: 968.

Journal article
Published: 07 May 2021 in Viruses
Reads 0
Downloads 0

Natural hosts of most arenaviruses are rodents. The human-pathogenic Lassa virus and several non-pathogenic arenaviruses such as Morogoro virus (MORV) share the same host species, namely Mastomys natalensis (M. natalensis). In this study, we investigated the history of infection and virus transmission within the natural host population. To this end, we infected M. natalensis at different ages with MORV and measured the health status of the animals, virus load in blood and organs, the development of virus-specific antibodies, and the ability of the infected individuals to transmit the virus. To explore the impact of the lack of evolutionary virus–host adaptation, experiments were also conducted with Mobala virus (MOBV), which does not share M. natalensis as a natural host. Animals infected with MORV up to two weeks after birth developed persistent infection, seroconverted and were able to transmit the virus horizontally. Animals older than two weeks at the time of infection rapidly cleared the virus. In contrast, MOBV-infected neonates neither developed persistent infection nor were able to transmit the virus. In conclusion, we demonstrate that MORV is able to develop persistent infection in its natural host, but only after inoculation shortly after birth. A related arenavirus that is not evolutionarily adapted to M. natalensis is not able to establish persistent infection. Persistently infected animals appear to be important to maintain virus transmission within the host population.

ACS Style

Chris Hoffmann; Stephanie Wurr; Elisa Pallasch; Sabrina Bockholt; Toni Rieger; Stephan Günther; Lisa Oestereich. Experimental Morogoro Virus Infection in Its Natural Host, Mastomys natalensis. Viruses 2021, 13, 851 .

AMA Style

Chris Hoffmann, Stephanie Wurr, Elisa Pallasch, Sabrina Bockholt, Toni Rieger, Stephan Günther, Lisa Oestereich. Experimental Morogoro Virus Infection in Its Natural Host, Mastomys natalensis. Viruses. 2021; 13 (5):851.

Chicago/Turabian Style

Chris Hoffmann; Stephanie Wurr; Elisa Pallasch; Sabrina Bockholt; Toni Rieger; Stephan Günther; Lisa Oestereich. 2021. "Experimental Morogoro Virus Infection in Its Natural Host, Mastomys natalensis." Viruses 13, no. 5: 851.

Articles
Published: 20 January 2021 in The Lancet Infectious Diseases
Reads 0
Downloads 0

Summary Background Lassa fever is endemic in several west African countries. Case-fatality rates ranging from 21% to 69% have been reported. The pathophysiology of the disease in humans and determinants of mortality remain poorly understood. We aimed to determine host protein biomarkers capable of determining disease outcome. Methods In this observational study, we analysed left-over blood samples from patients who tested positive for Lassa fever at Irrua Specialist Teaching Hospital, Nigeria, between January, 2014, and April, 2017. We measured viral load, concentrations of clinical chemistry parameters, and levels of 62 circulating proteins involved in inflammation, immune response, and haemostasis. Patients with a known outcome (survival or death) and at least 200 μL of good-quality diagnostic sample were included in logistic regression modelling to assess the correlation of parameters with Lassa fever outcome. Individuals who gave consent could further be enrolled into a longitudinal analysis to assess the association of parameters with Lassa fever outcome over time. Participants were divided into two datasets for the statistical analysis: a primary dataset (samples taken between Jan 1, 2014, and April 1, 2016), and a secondary dataset (samples taken between April 1, 2016, and April 1, 2017). Biomarkers were ranked by area under the receiver operating characteristic curve (AUC) from highest (most predictive) to lowest (least predictive). Findings Of 554 patients who tested positive for Lassa fever during the study period, 201 (131 in the primary dataset and 70 in the secondary dataset) were included in the biomarker analysis, of whom 74 (49 in the primary dataset and 25 in the secondary dataset) had died and 127 (82 in the primary dataset and 45 in the secondary dataset) had survived. Cycle threshold values (indicating viral load) and levels of 18 host proteins at the time of admission to hospital were significantly correlated with fatal outcome. The best predictors of outcome in both datasets were plasminogen activator inhibitor-1 (PAI-1; AUC 0·878 in the primary dataset and 0·876 in the secondary dataset), soluble thrombomodulin (TM; 0·839 in the primary dataset and 0·875 in the secondary dataset), and soluble tumour necrosis factor receptor superfamily member 1A (TNF-R1; 0·807 in the primary dataset and 0·851 in the secondary dataset), all of which had higher prediction accuracy than viral load (0·774 in the primary dataset and 0·837 in the secondary dataset). Longitudinal analysis (150 patients, of whom 36 died) showed that of the biomarkers that were predictive at admission, PAI-1 levels consistently decreased to normal levels in survivors but not in those who died. Interpretation The identification of PAI-1 and soluble TM as markers of fatal Lassa fever at admission, and of PAI-1 as a marker of fatal Lassa fever over time, suggests that dysregulated coagulation and fibrinolysis and endothelial damage have roles in the pathophysiology of Lassa fever, providing a mechanistic explanation for the association of Lassa fever with oedema and bleeding. These novel markers might aid in clinical risk stratification and disease monitoring. Funding German Research Foundation, Leibniz Association, and US National Institutes of Health.

ACS Style

Jamie Strampe; Danny A Asogun; Emily Speranza; Meike Pahlmann; Ali Soucy; Sabrina Bockholt; Elisa Pallasch; Beate Becker-Ziaja; Sophie Duraffour; Nahid Bhadelia; Yemisi Ighodalo; Jennifer Oyakhilome; Emmanuel O Omomoh; Thomas Olokor; Donatus I Adomeh; Odia Ikponwonsa; Chris Aire; Ekaete Tobin; Nosa Akpede; Peter O Okokhere; Sylvanus A Okogbenin; George O Akpede; César Muñoz-Fontela; Ephraim Ogbaini-Emovon; Stephan Günther; John H Connor; Lisa Oestereich. Factors associated with progression to death in patients with Lassa fever in Nigeria: an observational study. The Lancet Infectious Diseases 2021, 21, 876 -886.

AMA Style

Jamie Strampe, Danny A Asogun, Emily Speranza, Meike Pahlmann, Ali Soucy, Sabrina Bockholt, Elisa Pallasch, Beate Becker-Ziaja, Sophie Duraffour, Nahid Bhadelia, Yemisi Ighodalo, Jennifer Oyakhilome, Emmanuel O Omomoh, Thomas Olokor, Donatus I Adomeh, Odia Ikponwonsa, Chris Aire, Ekaete Tobin, Nosa Akpede, Peter O Okokhere, Sylvanus A Okogbenin, George O Akpede, César Muñoz-Fontela, Ephraim Ogbaini-Emovon, Stephan Günther, John H Connor, Lisa Oestereich. Factors associated with progression to death in patients with Lassa fever in Nigeria: an observational study. The Lancet Infectious Diseases. 2021; 21 (6):876-886.

Chicago/Turabian Style

Jamie Strampe; Danny A Asogun; Emily Speranza; Meike Pahlmann; Ali Soucy; Sabrina Bockholt; Elisa Pallasch; Beate Becker-Ziaja; Sophie Duraffour; Nahid Bhadelia; Yemisi Ighodalo; Jennifer Oyakhilome; Emmanuel O Omomoh; Thomas Olokor; Donatus I Adomeh; Odia Ikponwonsa; Chris Aire; Ekaete Tobin; Nosa Akpede; Peter O Okokhere; Sylvanus A Okogbenin; George O Akpede; César Muñoz-Fontela; Ephraim Ogbaini-Emovon; Stephan Günther; John H Connor; Lisa Oestereich. 2021. "Factors associated with progression to death in patients with Lassa fever in Nigeria: an observational study." The Lancet Infectious Diseases 21, no. 6: 876-886.

Preprint content
Published: 07 December 2020
Reads 0
Downloads 0

Background: SARS-CoV-2 molecular diagnostics is facing material shortages and long turnaround times due to exponential increase of testing demand. Objective: We evaluated the analytic performance and handling of four rapid Antigen Point of Care Tests (AgPOCTs) I-IV (Distributors: (I) Roche, (II) Abbott, (III) MEDsan and (IV) Siemens). Methods: 100 RT-PCR negative and 84 RT-PCR positive oropharyngeal swabs were prospectively collected and used to determine performance and accuracy of these AgPOCTs. Handling was evaluated by 10 healthcare workers/users through a questionnaire. Results: The median duration from symptom onset to sampling was 6 days (IQR 2-12 days). The overall relative sensitivity was 49.4%, 44.6%, 45.8% and 54.9 % for tests I, II, III and IV, respectively. In the high viral load subgroup (containing >106 copies of SARS-CoV-2 /swab, n=26), AgPOCTs reached sensitivities of 92.3% or more (range 92.3%-100%). Specificity was 100% for tests I, II and IV and 97% for test III. Regarding handling, test I obtained the overall highest scores, while test II was considered to have the most convenient components. Of note, users considered all assays, with the exception of test I, to pose a significant risk for contamination by drips or spills. Discussion: Besides some differences in sensitivity and handling, all four AgPOCTs showed acceptable performance in high viral load samples. However, due to the significantly lower sensitivity compared to RT-qPCR, a careful consideration of pro and cons of AgPOCT has to be taken into account before clinical implementation.

ACS Style

Flaminia Olearo; Dominik Noerz; Fabian Heinrich; Jan Peter Sutter; Kevin Roedel; Alexander Schultze; Julian Schulze Zur Wiesch; Platon Braun; Lisa Oesterreich; Benno Kreuels; Dominic Wichmann; Martin Aepfelbacher; Susanne Pfefferle; Marc Luetgehetmann. Handling and accuracy of four rapid antigen tests for the diagnosis of SARS-CoV-2 compared to RT-qPCR. 2020, 1 .

AMA Style

Flaminia Olearo, Dominik Noerz, Fabian Heinrich, Jan Peter Sutter, Kevin Roedel, Alexander Schultze, Julian Schulze Zur Wiesch, Platon Braun, Lisa Oesterreich, Benno Kreuels, Dominic Wichmann, Martin Aepfelbacher, Susanne Pfefferle, Marc Luetgehetmann. Handling and accuracy of four rapid antigen tests for the diagnosis of SARS-CoV-2 compared to RT-qPCR. . 2020; ():1.

Chicago/Turabian Style

Flaminia Olearo; Dominik Noerz; Fabian Heinrich; Jan Peter Sutter; Kevin Roedel; Alexander Schultze; Julian Schulze Zur Wiesch; Platon Braun; Lisa Oesterreich; Benno Kreuels; Dominic Wichmann; Martin Aepfelbacher; Susanne Pfefferle; Marc Luetgehetmann. 2020. "Handling and accuracy of four rapid antigen tests for the diagnosis of SARS-CoV-2 compared to RT-qPCR." , no. : 1.

Preprint content
Published: 12 October 2020
Reads 0
Downloads 0

Stroke and central nervous system dysfunction are cardinal symptoms in critically ill corona virus disease 19 (COVID-19) patients. In an autopsy series of 32 COVID-19 patients, we investigated whether carotid arteries were infected with SARS-CoV-2 by employing genomic, virologic, histochemical and transcriptomic analyses. We show that SARS-CoV-2 productively infects and modulates vascular responses in carotid arteries. This finding has far reaching implications for the understanding and clinical treatment of COVID-19.

ACS Style

Susanne Pfefferle; Thomas Guenther; Victor Puelles; Fabian Heinrich; Dominik Noerz; Manja Czech-Sioli; Alexander Carstens; Susanne Krasemann; Milagros Wong; Lisa Oestereich; Tim Magnus; Lena Allweiss; Caroline Edler; Ann-Sophie Schroeder; Maura Dandri; Tobias Huber; Markus Glatzel; Klaus Pueschel; Adam Grundhoff; Marc Luetgehetmann; Martin Aepfelbacher; Nicole Fischer. SARS-CoV-2 infects carotid arteries: implications for vascular disease and organ injury in COVID-19. 2020, 1 .

AMA Style

Susanne Pfefferle, Thomas Guenther, Victor Puelles, Fabian Heinrich, Dominik Noerz, Manja Czech-Sioli, Alexander Carstens, Susanne Krasemann, Milagros Wong, Lisa Oestereich, Tim Magnus, Lena Allweiss, Caroline Edler, Ann-Sophie Schroeder, Maura Dandri, Tobias Huber, Markus Glatzel, Klaus Pueschel, Adam Grundhoff, Marc Luetgehetmann, Martin Aepfelbacher, Nicole Fischer. SARS-CoV-2 infects carotid arteries: implications for vascular disease and organ injury in COVID-19. . 2020; ():1.

Chicago/Turabian Style

Susanne Pfefferle; Thomas Guenther; Victor Puelles; Fabian Heinrich; Dominik Noerz; Manja Czech-Sioli; Alexander Carstens; Susanne Krasemann; Milagros Wong; Lisa Oestereich; Tim Magnus; Lena Allweiss; Caroline Edler; Ann-Sophie Schroeder; Maura Dandri; Tobias Huber; Markus Glatzel; Klaus Pueschel; Adam Grundhoff; Marc Luetgehetmann; Martin Aepfelbacher; Nicole Fischer. 2020. "SARS-CoV-2 infects carotid arteries: implications for vascular disease and organ injury in COVID-19." , no. : 1.

Other
Published: 16 June 2020
Reads 0
Downloads 0

ObjectivesWe used viral genomics to deeply analyze the first SARS-CoV-2 infection clusters in the metropolitan region of Hamburg, Germany. Epidemiological analysis and contact tracing together with a thorough investigation of virus variant patterns revealed low and high infection dose transmissions to be involved in transmission events.MethodsInfection control measures were applied to follow up contract tracing. Metagenomic RNA- and SARS-CoV-2 amplicon sequencing was performed from 25 clinical samples for sequence analysis and variant calling.ResultsThe index patient acquired SARS-CoV-2 in Italy and after his return to Hamburg transmitted it to 2 out of 132 contacts. Virus genomics and variant pattern clearly confirms the initial local cluster. We identify frequent single nucleotide polymorphisms at positions 241, 3037, 14408, 23403 and 28881 previously described in Italian sequences and now considered as one major genotype in Europe. While the index patient showed a single nucleotide polymorphism only one variant was transmitted to the recipients. Different to the initial cluster, we observed in household clusters occurring at the time in Hamburg also intra-host viral species transmission events.ConclusionsSARS-CoV-2 variant tracing highlights both, low infection dose transmissions suggestive of fomites as route of infection in the initial cluster and high and low infection dose transmissions in family clusters indicative of fomites and droplets as infection routes. This suggests (1) single viral particle infection can be sufficient to initiate SARS-CoV-2 infection and (2) household/family members are exposed to high virus loads and therefore have a high risk to acquire SARS-CoV-2.

ACS Style

Susanne Pfefferle; Thomas Guenther; Robin Kobbe; Manja Czech-Sioli; Dominic Nörz; René Santer; Jun Oh; Stefan Kluge; Lisa Oestereich; Kersten Peldschus; Daniela Indenbirken; Jiabin Huang; Adam Grundhoff; Martin Aepfelbacher; Johannes K. Knobloch; Marc Luetgehetmann; Nicole Fischer. Low and high infection dose transmissions of SARS-CoV-2 in the first COVID-19 clusters in Northern Germany. 2020, 1 .

AMA Style

Susanne Pfefferle, Thomas Guenther, Robin Kobbe, Manja Czech-Sioli, Dominic Nörz, René Santer, Jun Oh, Stefan Kluge, Lisa Oestereich, Kersten Peldschus, Daniela Indenbirken, Jiabin Huang, Adam Grundhoff, Martin Aepfelbacher, Johannes K. Knobloch, Marc Luetgehetmann, Nicole Fischer. Low and high infection dose transmissions of SARS-CoV-2 in the first COVID-19 clusters in Northern Germany. . 2020; ():1.

Chicago/Turabian Style

Susanne Pfefferle; Thomas Guenther; Robin Kobbe; Manja Czech-Sioli; Dominic Nörz; René Santer; Jun Oh; Stefan Kluge; Lisa Oestereich; Kersten Peldschus; Daniela Indenbirken; Jiabin Huang; Adam Grundhoff; Martin Aepfelbacher; Johannes K. Knobloch; Marc Luetgehetmann; Nicole Fischer. 2020. "Low and high infection dose transmissions of SARS-CoV-2 in the first COVID-19 clusters in Northern Germany." , no. : 1.

Journal article
Published: 06 July 2018 in The Journal of Infectious Diseases
Reads 0
Downloads 0

Differences in T-cell phenotype, particularly the expression of markers of T-cell homeostasis, have been observed in fatal and nonfatal Ebola virus disease (EVD). However, the relationship between these markers with T-cell function and virus clearance during EVD is poorly understood. To gain biological insight into the role of T cells during EVD, combined transcriptomics and T-cell receptor sequencing was used to profile blood samples from fatal and nonfatal EVD patients from the recent West African EVD epidemic. Fatal EVD was characterized by strong T-cell activation and increased abundance of T-cell inhibitory molecules. However, the early T-cell response was oligoclonal and did not result in viral clearance. In contrast, survivors mounted highly diverse T-cell responses, maintained low levels of T-cell inhibitors, and cleared Ebola virus. Our findings highlight the importance of T-cell immunity in surviving EVD and strengthen the foundation for further research on targeting of the dendritic cell-T cell interface for postexposure immunotherapy.

ACS Style

Emily Speranza; Paula Ruibal; Julia Rebecca Port; Feng Feng; Lia Burkhardt; Adam Grundhoff; Stephan Günther; Lisa Oestereich; Julian Hiscox; John H Connor; César Muñoz-Fontela. T-Cell Receptor Diversity and the Control of T-Cell Homeostasis Mark Ebola Virus Disease Survival in Humans. The Journal of Infectious Diseases 2018, 218, S508 -S518.

AMA Style

Emily Speranza, Paula Ruibal, Julia Rebecca Port, Feng Feng, Lia Burkhardt, Adam Grundhoff, Stephan Günther, Lisa Oestereich, Julian Hiscox, John H Connor, César Muñoz-Fontela. T-Cell Receptor Diversity and the Control of T-Cell Homeostasis Mark Ebola Virus Disease Survival in Humans. The Journal of Infectious Diseases. 2018; 218 (suppl_5):S508-S518.

Chicago/Turabian Style

Emily Speranza; Paula Ruibal; Julia Rebecca Port; Feng Feng; Lia Burkhardt; Adam Grundhoff; Stephan Günther; Lisa Oestereich; Julian Hiscox; John H Connor; César Muñoz-Fontela. 2018. "T-Cell Receptor Diversity and the Control of T-Cell Homeostasis Mark Ebola Virus Disease Survival in Humans." The Journal of Infectious Diseases 218, no. suppl_5: S508-S518.

Journal article
Published: 01 January 2017 in The Lancet Global Health
Reads 0
Downloads 0

Summary Background By January, 2016, all known transmission chains of the Ebola virus disease (EVD) outbreak in west Africa had been stopped. However, there is concern about persistence of Ebola virus in the reproductive tract of men who have survived EVD. We aimed to use biostatistical modelling to describe the dynamics of Ebola virus RNA load in seminal fluid, including clearance parameters. Methods In this longitudinal study, we recruited men who had been discharged from three Ebola treatment units in Guinea between January and July, 2015. Participants provided samples of seminal fluid at follow-up every 3–6 weeks, which we tested for Ebola virus RNA using quantitative real-time RT-PCR. Representative specimens from eight participants were then inoculated into immunodeficient mice to test for infectivity. We used a linear mixed-effect model to analyse the dynamics of virus persistence in seminal fluid over time. Findings We enrolled 26 participants and tested 130 seminal fluid specimens; median follow up was 197 days (IQR 187–209 days) after enrolment, which corresponded to 255 days (228–287) after disease onset. Ebola virus RNA was detected in 86 semen specimens from 19 (73%) participants. Median duration of Ebola virus RNA detection was 158 days after onset (73–181; maximum 407 days at end of follow-up). Mathematical modelling of the quantitative time-series data showed a mean clearance rate of Ebola virus RNA from seminal fluid of −0·58 log units per month, although the clearance kinetic varied greatly between participants. Using our biostatistical model, we predict that 50% and 90% of male survivors clear Ebola virus RNA from seminal fluid at 115 days (90% prediction interval 72–160) and 294 days (212–399) after disease onset, respectively. We also predicted that the number of men positive for Ebola virus RNA in affected countries would decrease from about 50 in January 2016, to fewer than 1 person by July, 2016. Infectious virus was detected in 15 of 26 (58%) specimens tested in mice. Interpretation Time to clearance of Ebola virus RNA from seminal fluid varies greatly between individuals and could be more than 13 months. Our predictions will assist in decision-making about surveillance and preventive measures in EVD outbreaks. Funding This study was funded by European Union's Horizon 2020 research and innovation programme, Directorate-General for International Cooperation and Development of the European Commission, Institut national de la santé et de la recherche médicale (INSERM), German Research Foundation (DFG), and Innovative Medicines Initiative 2 Joint Undertaking.

ACS Style

Daouda Sissoko; Sophie Duraffour; Romy Kerber; Jacques Seraphin Kolie; Abdoul Habib Beavogui; Alseny-Modet Camara; Géraldine Colin; Toni Rieger; Lisa Oestereich; Bernadett Pályi; Stephanie Wurr; Jeremie Guedj; Thi Huyen Tram Nguyen; Rosalind M Eggo; Conall Watson; W John Edmunds; Joseph Akoi Bore; Fara Raymond Koundouno; Mar Cabeza-Cabrerizo; Lisa L Carter; Liana Eleni Kafetzopoulou; Eeva Kuisma; Janine Michel; Livia Victoria Patrono; Natasha Rickett; Katrin Singethan; Martin Rudolf; Angelika Lander; Elisa Pallasch; Sabrina Bockholt; Estefanía Rodríguez; Antonino Di Caro; Roman Wölfel; Martin Gabriel; Céline Gurry; Pierre Formenty; Sakoba Keïta; Denis Malvy; Miles W Carroll; Xavier Anglaret; Stephan Günther. Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study. The Lancet Global Health 2017, 5, e80 -e88.

AMA Style

Daouda Sissoko, Sophie Duraffour, Romy Kerber, Jacques Seraphin Kolie, Abdoul Habib Beavogui, Alseny-Modet Camara, Géraldine Colin, Toni Rieger, Lisa Oestereich, Bernadett Pályi, Stephanie Wurr, Jeremie Guedj, Thi Huyen Tram Nguyen, Rosalind M Eggo, Conall Watson, W John Edmunds, Joseph Akoi Bore, Fara Raymond Koundouno, Mar Cabeza-Cabrerizo, Lisa L Carter, Liana Eleni Kafetzopoulou, Eeva Kuisma, Janine Michel, Livia Victoria Patrono, Natasha Rickett, Katrin Singethan, Martin Rudolf, Angelika Lander, Elisa Pallasch, Sabrina Bockholt, Estefanía Rodríguez, Antonino Di Caro, Roman Wölfel, Martin Gabriel, Céline Gurry, Pierre Formenty, Sakoba Keïta, Denis Malvy, Miles W Carroll, Xavier Anglaret, Stephan Günther. Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study. The Lancet Global Health. 2017; 5 (1):e80-e88.

Chicago/Turabian Style

Daouda Sissoko; Sophie Duraffour; Romy Kerber; Jacques Seraphin Kolie; Abdoul Habib Beavogui; Alseny-Modet Camara; Géraldine Colin; Toni Rieger; Lisa Oestereich; Bernadett Pályi; Stephanie Wurr; Jeremie Guedj; Thi Huyen Tram Nguyen; Rosalind M Eggo; Conall Watson; W John Edmunds; Joseph Akoi Bore; Fara Raymond Koundouno; Mar Cabeza-Cabrerizo; Lisa L Carter; Liana Eleni Kafetzopoulou; Eeva Kuisma; Janine Michel; Livia Victoria Patrono; Natasha Rickett; Katrin Singethan; Martin Rudolf; Angelika Lander; Elisa Pallasch; Sabrina Bockholt; Estefanía Rodríguez; Antonino Di Caro; Roman Wölfel; Martin Gabriel; Céline Gurry; Pierre Formenty; Sakoba Keïta; Denis Malvy; Miles W Carroll; Xavier Anglaret; Stephan Günther. 2017. "Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study." The Lancet Global Health 5, no. 1: e80-e88.

Journal article
Published: 01 November 2015 in Antiviral Research
Reads 0
Downloads 0

International audienceThe polymerase inhibitor favipiravir is a candidate for the treatment of Ebola virus disease. Here, we designed a mathematical model to characterize the viral dynamics in 20 mice experimentally infected with Ebola virus, which were either left untreated or treated with favipiravir at 6 or 8 days post infection. This approach provided estimates of kinetic parameters of Ebola virus reproduction, such as the half-life of productively infected cells, of about 6 hours, and the basic reproductive number which indicates that virus produced by a single infected cell productively infects about 9 new cells. Furthermore, the model predicted that favipiravir efficiently blocks viral production, reaching an antiviral effectiveness of 95% and 99.6% at 2 and 6 days after initiation of treatment, respectively. The model could be particularly helpful to guide future studies evaluating favipiravir in larger animals

ACS Style

Vincent Madelain; Lisa Oestereich; Frederik Graw; Thi Huyen Tram Nguyen; Xavier de Lamballerie; France Mentré; Stephan Günther; Jeremie Guedj. Ebola virus dynamics in mice treated with favipiravir. Antiviral Research 2015, 123, 70 -77.

AMA Style

Vincent Madelain, Lisa Oestereich, Frederik Graw, Thi Huyen Tram Nguyen, Xavier de Lamballerie, France Mentré, Stephan Günther, Jeremie Guedj. Ebola virus dynamics in mice treated with favipiravir. Antiviral Research. 2015; 123 ():70-77.

Chicago/Turabian Style

Vincent Madelain; Lisa Oestereich; Frederik Graw; Thi Huyen Tram Nguyen; Xavier de Lamballerie; France Mentré; Stephan Günther; Jeremie Guedj. 2015. "Ebola virus dynamics in mice treated with favipiravir." Antiviral Research 123, no. : 70-77.

Case reports
Published: 01 February 2015 in Journal of Clinical Virology
Reads 0
Downloads 0

We report the first two cases of laboratory confirmed Zika virus (ZIKV) infections imported into Italy from French Polynesia. Both patients presented with low grade fever, malaise, conjunctivitis, myalgia, arthralgia, ankle oedema, and axillary and inguinal lymphadenopathy. One patient showed leukopenia with relative monocytosis and thrombocytopenia. The diagnosis was based on ZIKV seroconversion in both cases and on ZIKV RNA detection in one patient from acute serum sample. Sera from both patients exhibited cross-reactivity with dengue virus antigens. Our immunological analysis demonstrated that recovery from ZIKV infection is associated with restoration of normal numbers of immune cells in the periphery as well as with normal function of antigen-presenting cells. ZIKV is an emerging arbovirus, which has recently spread extensively in tourist destinations on several West Pacific islands. Returning viremic travelers may ignite autochthonous infections in countries like Italy, which are infested by Aedes albopictus, a suitable vector for ZIKV. The role of clinicians is crucial and includes early diagnosis and timely notification of public health authorities in order to quickly implement adequate focal vector control measurements.

ACS Style

Lorenzo Zammarchi; Giulia Stella; Antonia Mantella; Dario Bartolozzi; Dennis Tappe; Stephan Günther; Lisa Oestereich; Daniel Cadar; César Muñoz-Fontela; Alessandro Bartoloni; Jonas Schmidt-Chanasit. Zika virus infections imported to Italy: Clinical, immunological and virological findings, and public health implications. Journal of Clinical Virology 2015, 63, 32 -35.

AMA Style

Lorenzo Zammarchi, Giulia Stella, Antonia Mantella, Dario Bartolozzi, Dennis Tappe, Stephan Günther, Lisa Oestereich, Daniel Cadar, César Muñoz-Fontela, Alessandro Bartoloni, Jonas Schmidt-Chanasit. Zika virus infections imported to Italy: Clinical, immunological and virological findings, and public health implications. Journal of Clinical Virology. 2015; 63 ():32-35.

Chicago/Turabian Style

Lorenzo Zammarchi; Giulia Stella; Antonia Mantella; Dario Bartolozzi; Dennis Tappe; Stephan Günther; Lisa Oestereich; Daniel Cadar; César Muñoz-Fontela; Alessandro Bartoloni; Jonas Schmidt-Chanasit. 2015. "Zika virus infections imported to Italy: Clinical, immunological and virological findings, and public health implications." Journal of Clinical Virology 63, no. : 32-35.

Journal article
Published: 09 October 2014 in New England Journal of Medicine
Reads 0
Downloads 0

International audience: In March 2014, the World Health Organization was notified of an outbreak of a communicable disease characterized by fever, severe diarrhea, vomiting, and a high fatality rate in Guinea. Virologic investigation identified Zaire ebolavirus (EBOV) as the causative agent. Full-length genome sequencing and phylogenetic analysis showed that EBOV from Guinea forms a separate clade in relationship to the known EBOV strains from the Democratic Republic of Congo and Gabon. Epidemiologic investigation linked the laboratory-confirmed cases with the presumed first fatality of the outbreak in December 2013. This study demonstrates the emergence of a new EBOV strain in Guinea

ACS Style

Sylvain Baize; Delphine Pannetier; Lisa Oestereich; Toni Rieger; Lamine Koivogui; N'faly Magassouba; Barrè Soropogui; Mamadou Saliou Sow; Sakoba Keïta; Hilde De Clerck; Amanda Tiffany; Gemma Dominguez; Mathieu Loua; Alexis Traoré; Moussa Kolié; Emmanuel Roland Malano; Emmanuel Heleze; Anne Bocquin; Stephane Mely; Hervé Raoul; Valérie Caro; Dániel Cadar; Martin Gabriel; Meike Pahlmann; Dennis Tappe; Jonas Schmidt-Chanasit; Benido Impouma; Abdoul Karim Diallo; Pierre Formenty; Michel Van Herp; Stephan Günther. Emergence of Zaire Ebola Virus Disease in Guinea. New England Journal of Medicine 2014, 371, 1418 -1425.

AMA Style

Sylvain Baize, Delphine Pannetier, Lisa Oestereich, Toni Rieger, Lamine Koivogui, N'faly Magassouba, Barrè Soropogui, Mamadou Saliou Sow, Sakoba Keïta, Hilde De Clerck, Amanda Tiffany, Gemma Dominguez, Mathieu Loua, Alexis Traoré, Moussa Kolié, Emmanuel Roland Malano, Emmanuel Heleze, Anne Bocquin, Stephane Mely, Hervé Raoul, Valérie Caro, Dániel Cadar, Martin Gabriel, Meike Pahlmann, Dennis Tappe, Jonas Schmidt-Chanasit, Benido Impouma, Abdoul Karim Diallo, Pierre Formenty, Michel Van Herp, Stephan Günther. Emergence of Zaire Ebola Virus Disease in Guinea. New England Journal of Medicine. 2014; 371 (15):1418-1425.

Chicago/Turabian Style

Sylvain Baize; Delphine Pannetier; Lisa Oestereich; Toni Rieger; Lamine Koivogui; N'faly Magassouba; Barrè Soropogui; Mamadou Saliou Sow; Sakoba Keïta; Hilde De Clerck; Amanda Tiffany; Gemma Dominguez; Mathieu Loua; Alexis Traoré; Moussa Kolié; Emmanuel Roland Malano; Emmanuel Heleze; Anne Bocquin; Stephane Mely; Hervé Raoul; Valérie Caro; Dániel Cadar; Martin Gabriel; Meike Pahlmann; Dennis Tappe; Jonas Schmidt-Chanasit; Benido Impouma; Abdoul Karim Diallo; Pierre Formenty; Michel Van Herp; Stephan Günther. 2014. "Emergence of Zaire Ebola Virus Disease in Guinea." New England Journal of Medicine 371, no. 15: 1418-1425.

Journal article
Published: 01 May 2014 in Antiviral Research
Reads 0
Downloads 0

Outbreaks of Ebola hemorrhagic fever in sub-Saharan Africa are associated with case fatality rates of up to 90%. Currently, neither a vaccine nor an effective antiviral treatment is available for use in humans. Here, we evaluated the efficacy of the pyrazinecarboxamide derivative T-705 (favipiravir) against Zaire Ebola virus (EBOV) in vitro and in vivo. T-705 suppressed replication of Zaire EBOV in cell culture by 4log units with an IC90 of 110μM. Mice lacking the type I interferon receptor (IFNAR−/−) were used as in vivo model for Zaire EBOV-induced disease. Initiation of T-705 administration at day 6 post infection induced rapid virus clearance, reduced biochemical parameters of disease severity, and prevented a lethal outcome in 100% of the animals. The findings suggest that T-705 is a candidate for treatment of Ebola hemorrhagic fever

ACS Style

Lisa Oestereich; Anja Lüdtke; Stephanie Wurr; Toni Rieger; Cesar Munoz-Fontela; Stephan Günther. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Research 2014, 105, 17 -21.

AMA Style

Lisa Oestereich, Anja Lüdtke, Stephanie Wurr, Toni Rieger, Cesar Munoz-Fontela, Stephan Günther. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Research. 2014; 105 ():17-21.

Chicago/Turabian Style

Lisa Oestereich; Anja Lüdtke; Stephanie Wurr; Toni Rieger; Cesar Munoz-Fontela; Stephan Günther. 2014. "Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model." Antiviral Research 105, no. : 17-21.